BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh
BBCi CATEGORIES   TV   RADIO   COMMUNICATE   WHERE I LIVE   INDEX    SEARCH 

BBC NEWS
 You are in:  Health
Front Page 
World 
UK 
UK Politics 
Business 
Sci/Tech 
Health 
Background Briefings 
Medical notes 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


Commonwealth Games 2002

BBC Sport

BBC Weather

SERVICES 
Friday, 26 April, 2002, 23:10 GMT 00:10 UK
Hepatitis C immunity vaccine hope
Blood bag
The virus affects sufferers' blood
Some drug users who contract the hepatitis C virus infection may be able to build up an immunity against the disease, a study suggests.

The findings could help scientists develop a vaccine to protect drug users and other groups most at risk of contracting the disease.

About four million people in the United States and 170m people worldwide have been infected with the hepatitis C virus (HCV), for which, unlike hepatitis A and B, there is no vaccine.

About 85% of people infected with HCV develop persistent infection and are at risk of long-term complications, including liver cirrhosis and liver cancer.


We desperately need a vaccine

Nigel Hughes, British Liver Trust
HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and symptoms of the disease after they were reinfected.

David Thomas and colleagues from Johns Hopkins School of Medicine in Baltimore, USA, aimed to establish whether similar immunity could be achieved in people, according to an article in The Lancet medical journal.

They selected injecting drug users and identified 164 who had no evidence of previous HCV infection and another 98 who had been previously infected with HCV, but had cleared the infection.

The incidence of HCV infection was halved for people who had been previously infected, compared with those who had not been previously infected (12% and 21% respectively).

Creative research

David Thomas said: "The high rate of HCV infection in injecting-drug users underscores the importance of preventing HCV infection.

"Since it appears that immunity can be acquired to protect against viral persistence, vaccines should be tested to reduce the medical consequences of HCV infection among people at highest risk."

Hepatitis C causes jaundice, fatigue, abdominal pain, nausea and loss of appetite.

David Grant, from the Memorial University of Newfoundland, Canada, said: "While the most positive interpretation of this unique study offers hope that protection against HCV can be acquired, the immunogenicity of human vaccines still pales compared with that of genuine infections.

"The need for continued creative research in vaccine design is emphatically underlined by the, at best, part-protection against persistent secondary infection conferred by clearance of primary infection with HCV itself."

The British Liver Trust is optimistic about the research.

The trust's chief executive Nigel Hughes said: "We don't fully understand the mechanisms of immunity.

"This is an interesting development and I would hope more studies are done and it's replicated on a wider scale.

"This could kick-start the research even more.

"We desperately need a vaccine."

See also:

23 May 01 | Health
Hepatitis C alert at hospitals
06 Apr 01 | Scotland
Fury over hepatitis C decision
01 Oct 01 | Health
Liver damage prevented
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories